UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1372-5
Program Prior Authorization/Notification
Medication Opzelura® (ruxolitinib)
P&T Approval Date 11/2021, 4/2022, 9/2022, 9/2023, 12/2024
Effective Date 3/1/2025
1. Background:
Opzelura (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the topical short term and
non-continuous chronic treatment of mild to moderate atopic dermatitis in non-
immunocompromised patients 12 years of age and older whose disease is not adequately
controlled with topical prescription therapies or when those therapies are not advisable. Opzelura
is also indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients
12 years of age and older.
Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors or potent
immunosuppressants such as azathioprine or cyclosporine is not recommended.
2. Coverage Criteriaa:
A. Atopic Dermatitis
1. Initial Authorization
a. Opzelura will be approved based on all of the following criteria:
(1) Diagnosis of mild to moderate atopic dermatitis
-AND-
(2) History of failure, contraindication, or intolerance to topical therapies (e.g.,
topical corticosteroids, topical calcineurin inhibitors)
-AND-
(3) Patient is not receiving Opzelura in combination with another biologic
medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan
(rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor
[e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
-AND-
(4) Patient is not receiving Opzelura in combination with a potent
immunosuppressant medication (e.g., azathioprine, cyclosporine)
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
1
2. Reauthorization
a. Opzelura will be approved based all of the following criteria:
(1) Documentation of positive clinical response to therapy
-AND-
(2) Patient is not receiving Opzelura in combination with another biologic
medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan
(rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor
[e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
-AND-
(3) Patient is not receiving Opzelura in combination with a potent
immunosuppressant medication (e.g., azathioprine, cyclosporine)
Authorization will be issued for 12 months.
B. Nonsegmental Vitiligo
1. Initial Authorization
a. Opzelura will be approved based on all of the following criteria:
(1) Diagnosis of nonsegmental vitiligo
-AND-
(2) Patient is not receiving Opzelura in combination with another biologic
medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan
(rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor
[e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
-AND-
(3) Patient is not receiving Opzelura in combination with a potent
immunosuppressant medication (e.g., azathioprine, cyclosporine)
Authorization will be issued for 12 months.
2. Reauthorization
a. Opzelura will be approved based all of the following criteria:
(1) Documentation of positive clinical response to therapy
-AND-
© 2024 UnitedHealthcare Services, Inc.
2
(2) Patient is not receiving Opzelura in combination with another biologic
medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan
(rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor
[e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
-AND-
(3) Patient is not receiving Opzelura in combination with a potent
immunosuppressant medication (e.g., azathioprine, cyclosporine)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Opzelura [package insert]. Wilmington, DE: Incyte Corporation; August 2024.
Program Prior Authorization/Notification - Opzelura (ruxolitinib)
Change Control
11/2021 New program.
4/2022 Changed initial authorization duration from 8 weeks to 12 months.
9/2022 Added coverage criteria for nonsegmental vitiligo. Updated
background, examples, and reference. Added state mandate footnote.
9/2023 Annual review with no change to clinical criteria. Updated reference.
12/2024 Annual review. Removed age requirement criteria. Updated vitiligo
initial authorization to 12 months. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
3